Purchase this article with an account.
J. Noble, C. Birt, L. Derzko–Dzulynsky, T. Rabinovitch; Outcome of Trabeculectomy With Intra–Operative Mitomycin C for Uveitic Glaucoma . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5488.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The purpose of this study was to compare the outcome of Mitomycin C (MMC) augmented trabeculectomy in glaucoma patients with uveitis to those without uveitis but with other high risk characteristics.
Fifty–one eyes of 51 patients (21 uveitic patients and 30 non–uveitic patients) were included in the study. Two outcome classifications were analyzed: absolute success (IOP < 30% baseline without glaucoma medications or 5–Fluorouracil (5–FU) injections), and qualified success (IOP < 30% baseline with glaucoma medications or 5–FU injections). Kaplan–Meier survival curves were constructed for both models.
After a mean follow up of 52 months, uveitis emerged as a negative predictor of success. In the qualified success model, uveitic patients demonstrated survival rates of 90% and 79% at 1 and 2 years compared to 100% for all time points in the control group (wilcoxon test, p=0.005). Uveitic patients were more likely to require postoperative 5–FU injections than the control group (33% vs. 10%, respectively, p=0.039) and were more likely to require glaucoma medications postoperatively for IOP control (38% vs. 3%, respectively, p=0.001).
Uveitic glaucoma patients are more likely to require post–operative therapeutic interventions to maintain adequate pressure control in the short–term and are at higher risk of surgical failure in the long–term.
This PDF is available to Subscribers Only